NVS   $115.94  -0.03% Market Closed After Close 115.94 0.0

Novartis AG
Last Events:

2023-08-09 Trend pattern changed from расширяющаяся формация to расходящийся треугольник.

2023-08-09 Signal in Stochastic changed from bearish to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-05 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-04 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.

2023-08-03 Signal in MACD changed from bullish to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.


Current temperature: 0.00
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 118.35
High with % probability:
Analyst Recommendations:
Number of estimates 10
Target Price Mean 117.31
Mean unverified/preliminary 117.31 / 117.31
Target Price Low / High 97.00 / 130.00
Median / STD DEV 119.50 / 10.32
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Sell Sell
rsi ActivelyBuy Buy None
macd None None None
stoch None None None
ma20 None Sell Sell
ma50 None None None
ma100 None Sell None
Candlestick PatternSept. 10, 2024 Dragon Fly - is formed when the opening and the closing prices are at the highest of the day. If it has a longer lower shadow it signals a more bullish trend. When appearing at market bottoms it is considered to be a reversal signal.
ISIN US66987V1098
Website https://www.novartis.com
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.